SUPN: Supernus Pharmaceuticals, Inc. - Summary | Jitta

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Price
$29.90
Loss Chance
42.1%
5.47JITTA SCORE
28.71%Under Jitta Line
Jitta Ranking
117 / 1,098
1,433 / 4,703
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (55)
Recent Business Performance (27)
Financial Strength (82)
Return to Shareholders (43)
Competitive Advantage (65)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Return on EquityConsistently High
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Recent Business PerformanceEarning decline 43.64% in the last quarter (yoy)
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.47
28.71%
2.00
308.27%
2.24
423.78%
Pharmaceuticals
5.03
67.61%
5.61
21.12%
3.76
64.15%
COMPANY DESCRIPTION
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company’s commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.